Picture of PMD Device Solutions AB logo

PMDS PMD Device Solutions AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-25.51%
3m-79.74%
6m-14.04%
1yr-77.98%
Volume Change (%)
10d/3m-18.2%
Price vs... (%)
52w High-93.52%
50d MA-24.53%
200d MA-46.54%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-70.01%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
23rd Dec 202423rd Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of PMD Device Solutions AB EPS forecast chart

Profile Summary

PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.

Directors

    Last Annual
    December 23rd, 2023
    Last Interim
    December 23rd, 2023
    Incorporated
    January 29th, 2003
    Public Since
    July 6th, 2017
    No. of Employees
    1
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    se flag iconOMX Nordic Exchange Stockholm
    Shares in Issue
    474,175.84
    Blurred out image of a map
    Address
    Fogdevreten 2 B, SOLNA, 171 65
    Web
    Phone
    +46 850884744
    Auditors
    Finnhammars Revisionsbyra

    PMDS Share Price Performance

    Upcoming Events for PMDS

    Similar to PMDS

    Picture of 2cureX AB logo

    2cureX AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Abliva AB logo

    Abliva AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Acousort AB logo

    Acousort AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Active Biotech AB publ logo

    Active Biotech AB publ

    se flag iconOMX Nordic Exchange Stockholm

    Picture of AddLife AB logo

    AddLife AB

    se flag iconOMX Nordic Exchange Stockholm

    FAQ